Influenza (Pandemic)
6
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu